Modern Drug Synthesis
(Sprache: Englisch)
Following Contemporary Drug Synthesis and The Art of Drug Synthesis (Wiley, 2004 and 2007), two well-received works, is this new book that demystifies the process of modern drug discovery for practitioners and students. An enhanced introduction covers areas...
Leider schon ausverkauft
versandkostenfrei
Buch (Gebunden)
Fr. 202.90
inkl. MwSt.
- Kreditkarte, Paypal, Rechnungskauf
- 30 Tage Widerrufsrecht
Produktdetails
Produktinformationen zu „Modern Drug Synthesis “
Klappentext zu „Modern Drug Synthesis “
Following Contemporary Drug Synthesis and The Art of Drug Synthesis (Wiley, 2004 and 2007), two well-received works, is this new book that demystifies the process of modern drug discovery for practitioners and students. An enhanced introduction covers areas such as background, pharmacology, SAR, PK/PD, efficacy, and safety. Focusing on the advantages of process synthesis versus the discovery synthetic route, Modern Drug Synthesis features authoritative coverage by distinguished editors and authors (some chapter authors are the actual inventor of the drug) of twenty different drug molecules.
Inhaltsverzeichnis zu „Modern Drug Synthesis “
Preface.Contributors.
I. Infectious Diseases.
Chapter 1. Raltegravir (Isentress), The First-in-class HIV-1 Integrase Inhibitor (Julianne A. Hunt).
1.1 Background.
1.2 Pharmacology.
1.3 Structure-Activity Relationship (SAR).
1.4 Pharmacokinetics and Drug Metabolism.
1.5 Efficacy and Safety.
1.6 Syntheses.
1.7 References.
Chapter 2. Maraviroc (Selzentry), The First-in-class CCR5 Antagonist for the Treatment of HIV (David Price).
2.1 Background.
2.2 Structure-Activity Relationship (SAR).
2.3 Pharmacokinetics and Safety.
2.4 Syntheses.
2.5 References.
Chapter 3. Darunavir (Prezista), A HIV-1 Protease Inhibitor for Treatment of Multidrug Resistant HIV (Arun K. Ghosh and Cuthbert D. Martyr).
3.1 Background.
3.2 Pharmacology.
3.3 Structure-Activity Relationship (SAR).
3.4 Pharmacokinetics and Drug Metabolism.
3.5 Efficacy and Safety.
3.6 Syntheses.
3.7 References.
II. Cancer.
Chapter 4. Decitabine (Dacogen), A DNA Methyltransferase Inhibitor for Cancer (Jennifer A. Van Camp).
4.1 Background.
4.2 Pharmacology.
4.3 Structure-Activity Relationship (SAR).
4.4 Pharmacokinetics and Drug Metabolism.
4.5 Efficacy and Safety.
4.6 Syntheses.
4.7 References.
Chapter 5. Capecitabine (Xeloda), An Oral Chemotherapy Agent (R. Jason Herr).
5.1 Background.
5.2 Pharmacology.
5.3 Structure-Activity Relationship (SAR).
5.4 Pharmacokinetics and Efficacy.
5.5 Syntheses.
5.6 References.
Chapter 6. Sorafenib (Nexavar), A Multi-kinase Inhibitor for Advanced Renal Cell Carcinoma and Unresectable Hepatocellular Carcinoma (Shuanghua Hu).
6.1 Background.
6.2 Pharmacology.
6.3 Structure-Activity Relationship
... mehr
(SAR).
6.4 Pharmacokinetics and Drug Metabolism.
6.5 Efficacy and Safety.
6.6 Syntheses.
6.7 References.
Chapter 7. Sunitinib (Sutent), An Angiogenesis Inhibitor (Martin Pettersson).
7.1 Background.
7.2 Discovery and Development.
7.3 Syntheses.
7.3.1 Discovery Route.
7.3.2 Process Route.
7.4 References.
Chapter 8. Bortezomib (Velcade), A First-in-class Proteasome Inhibitor (Benjamin S. Greener and David S. Millan).
8.1 Background.
8.2 Pharmacology.
8.3 Structure-Activity Relationship (SAR).
8.4 Pharmacokinetics and Drug Metabolism.
8.5 Efficacy and Safety.
8.6 Syntheses.
8.7 References.
Chapter 9. Pazopanib (Votrient), A VEGFR Tyrosine Kinase Inhibitor for Cancer (Ji Zhang and Jie Jack Li).
9.1 Background.
9.2 Pharmacology.
9.3 Structure-Activity Relationship (SAR).
9.4 Pharmacokinetics and Drug Metabolism.
9.5 Efficacy and Safety.
9.6 Syntheses.
9.7 Other VEGFR Inhibitors in Development: Vandetanib and Cediranib.
9.8 References.
III. Cardiovascular and Metabolic Diseases.
Chapter 10. Sitagliptin (Januvia), A Treatment for Type 2 Diabetes (Scott D. Edmondson, Feng Xu, and Joseph D. Armstrong III).
10.1 Background.
10.2 Pharmacology.
10.3 Structure-Activity Relationship (SAR).
10.4 Pharmacokinetics and Drug Metabolism.
10.5 Efficacy and Safety.
10.6 Syntheses.
10.7 References.
Chapter 11. Aliskiren (Tekturna), The
6.4 Pharmacokinetics and Drug Metabolism.
6.5 Efficacy and Safety.
6.6 Syntheses.
6.7 References.
Chapter 7. Sunitinib (Sutent), An Angiogenesis Inhibitor (Martin Pettersson).
7.1 Background.
7.2 Discovery and Development.
7.3 Syntheses.
7.3.1 Discovery Route.
7.3.2 Process Route.
7.4 References.
Chapter 8. Bortezomib (Velcade), A First-in-class Proteasome Inhibitor (Benjamin S. Greener and David S. Millan).
8.1 Background.
8.2 Pharmacology.
8.3 Structure-Activity Relationship (SAR).
8.4 Pharmacokinetics and Drug Metabolism.
8.5 Efficacy and Safety.
8.6 Syntheses.
8.7 References.
Chapter 9. Pazopanib (Votrient), A VEGFR Tyrosine Kinase Inhibitor for Cancer (Ji Zhang and Jie Jack Li).
9.1 Background.
9.2 Pharmacology.
9.3 Structure-Activity Relationship (SAR).
9.4 Pharmacokinetics and Drug Metabolism.
9.5 Efficacy and Safety.
9.6 Syntheses.
9.7 Other VEGFR Inhibitors in Development: Vandetanib and Cediranib.
9.8 References.
III. Cardiovascular and Metabolic Diseases.
Chapter 10. Sitagliptin (Januvia), A Treatment for Type 2 Diabetes (Scott D. Edmondson, Feng Xu, and Joseph D. Armstrong III).
10.1 Background.
10.2 Pharmacology.
10.3 Structure-Activity Relationship (SAR).
10.4 Pharmacokinetics and Drug Metabolism.
10.5 Efficacy and Safety.
10.6 Syntheses.
10.7 References.
Chapter 11. Aliskiren (Tekturna), The
... weniger
Autoren-Porträt von Johnson, Li
JIE JACK LI is a chemist at Bristol-Myers Squibb Company in Wallingford, Connecticut. He is the coauthor of various books, including Palladium in Heterocyclic Chemistry, Name Reactions: A Collection of Detailed Reaction Mechanisms and Synthetic Applications, Name Reactions in Heterocyclic Chemistry, Contemporary Drug Synthesis, The Art of Drug Synthesis, Name Reactions for Functional Group Transformations, Name Reactions for Homologations, Parts 1 and 2, and Name Reactions for Carbocyclic Ring Formations.DOUGLAS JOHNSON is a medicinal chemist and project leader at Pfizer in Groton, Connecticut. He is a coauthor on more than forty publications and patents, including the books The Art of Drug Synthesis and Contemporary Drug Synthesis.
Rezension zu „Modern Drug Synthesis “
"All chapters are very well written, and the used schemes and tables are conveniently arranged. The information and explanations given are strengthened by well-chosen examples and so the reader can easily follow the discussion. The comprehensive referenced literature placed at the end of each chapter enables further reading, and a detailed keyword index in combination with a logically structured Table of Content allows fast access to the topic of interest." (ChemMedChem, 2010)
Pressezitat
"All chapters are very well written, and the used schemes and tables are conveniently arranged. The information and explanations given are strengthened by well-chosen examples and so the reader can easily follow the discussion. The comprehensive referenced literature placed at the end of each chapter enables further reading, and a detailed keyword index in combination with a logically structured Table of Content allows fast access to the topic of interest." ( ChemMedChem , 2010)Kommentar zu "Modern Drug Synthesis"
0 Gebrauchte Artikel zu „Modern Drug Synthesis“
| Zustand | Preis | Porto | Zahlung | Verkäufer | Rating |
|---|
Schreiben Sie einen Kommentar zu "Modern Drug Synthesis".
Kommentar verfassen